LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) insider Danish J. Qureshi sold 12,965 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $5.93, for a total transaction of $76,882.45. Following the completion of the sale, the insider now directly owns 4,911,050 shares of the company’s stock, valued at approximately $29,122,526.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
LifeStance Health Group Stock Performance
Shares of LifeStance Health Group stock remained flat at $5.71 on Friday. The stock had a trading volume of 859,166 shares, compared to its average volume of 1,309,593. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -11.20 and a beta of 1.34. LifeStance Health Group, Inc. has a fifty-two week low of $4.74 and a fifty-two week high of $9.59. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.11. The stock has a fifty day moving average price of $6.53 and a 200-day moving average price of $6.55.
LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.03). LifeStance Health Group had a negative return on equity of 12.66% and a negative net margin of 17.64%. The company had revenue of $280.60 million during the quarter, compared to analyst estimates of $263.14 million. As a group, sell-side analysts forecast that LifeStance Health Group, Inc. will post -0.3 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
LFST has been the subject of several research analyst reports. Barclays boosted their price objective on LifeStance Health Group from $7.00 to $8.00 and gave the company an “underweight” rating in a report on Thursday, February 29th. The Goldman Sachs Group boosted their price target on LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Monday, March 4th. Finally, Jefferies Financial Group raised their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $8.60.
Read Our Latest Report on LFST
LifeStance Health Group Company Profile
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Further Reading
- Five stocks we like better than LifeStance Health Group
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Comprehensive Analysis of PayPal Stock
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Insider Trades May Not Tell You What You Think
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.